Here is Why Veradermics (MANE) is One of the Best Performing NYSE Stocks So Far in 2026

Published on May 20, 2026 at 11:02 pm by Maham Fatima in News

Veradermics Inc. (NYSE:MANE) is one of the best performing NYSE stocks so far in 2026. On May 12, Veradermics reported a net loss of $27.2 million for Q1 2026, compared to a net loss of $12.4 million in the prior-year period. Driven by the late-stage clinical progress of its main pipeline asset, VDPHL01, R&D expenses rose to $20.9 million, while G&A costs climbed to $8.9 million. The company closed the quarter with $390.8 million in cash, which was later supported by a post-quarter follow-on offering, bringing total 2026 gross proceeds to $766.8 million, extending its operational runway into 2030.

On the clinical front, Veradermics achieved a major milestone by reporting positive Phase 2/3 topline data from Part A of its Study ‘302’ for males with mild-to-moderate pattern hair loss/PHL. The investigational, extended-release minoxidil tablet met its goals for robust hair growth with a favorable safety profile, positioning it to potentially become the first FDA-approved oral treatment for PHL in nearly 30 years. The company expects to share full 12-month data from this trial in H2 2026.

Veradermics Inc. (NYSE:MANE) expects multiple data readouts in the second half of 2026, including topline data from its confirmatory Phase 3 Study ‘304’ in males, which completed enrollment in February. Additionally, the company is actively enrolling female patients in its Phase 2/3 Study ‘306’. If approved, VDPHL01 would establish a new commercial footprint as the only FDA-approved non-hormonal oral therapy for both male and female pattern hair loss.

Veradermics Inc. (NYSE:MANE) is a late clinical-stage biopharmaceutical company with a focus on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent dermatological and aesthetic conditions.

Disclosure: None. Follow Insider Monkey on Google News.